Pfizer and BioNTech urge US patent review board to take on Moderna's Covid patents
Pfizer and BioNTech have once again made their case for the US Patent Trial and Appeal Board (PTAB) to weigh in on a Covid-19 patent dispute with Moderna, following up on a request for review of their claims despite a parallel case ongoing in federal court.
The three companies have been fighting over the venues in which the allegations will be heard. Last month, Moderna urged the PTAB to reject Pfizer and BioNTech’s request for review, and to let the court case play out. The Cambridge, MA biotech argued that Pfizer and BioNTech were trying to get “two bites at the invalidity apple.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.